OptiBiotix Health PLC Non-exclusive distribution agreement for SlimBiome (3647C)
October 01 2018 - 2:00AM
UK Regulatory
TIDMOPTI
RNS Number : 3647C
OptiBiotix Health PLC
01 October 2018
OptiBiotix Health plc
("OptiBiotix" or the "Company")
Non-exclusive distribution agreement for SlimBiome(R)
OptiBiotix Health plc (AIM: OPTI), a life sciences business
developing compounds to tackle obesity, high cholesterol, diabetes
and skin care, announces it has entered into a distribution
agreement with CTC Holding BV ("CTC Group"). The agreement grants
CTC Group a non-exclusive licence to distribute OptiBiotix's
SlimBiome(R) weight management technology in the Philippines,
Vietnam, Indonesia and Colombia.
CTC Group is an international privately-owned company
established in the 1890s with 12 sales offices covering Europe,
South and Central America, Caribbean and China, with its
headquarters in Amsterdam. They provide innovative and value-added
solutions for food, beverages and personal care products, focusing
on natural, functional and scientific ingredients.
SlimBiome(R), a patented combination of natural ingredients
developed by nutritional experts to provide hunger free weight loss
will be promoted as part of their food innovation and solutions
platforms. This agreement will extend SlimBiome's(R) commercial
reach into the ASEAN and South American markets where functional
ingredients and supplements play a vital role in weight management,
health and beauty. The Philippines has a growing population with an
increase in obesity related health issues as a result of adopting a
more western diet. The CTC Group views both SlimBiome (R) and
SlimBiome products as being the ideal solution to address this
need.
The CTC Group will use its best endeavours to develop and expand
the use of SlimBiome (R) through their customer network as well as
existing partnerships focused on weight management and healthy
living.
Christina Wood, Sales & Marketing Director of OptiBiotix,
commented: "We are pleased to announce the signing of this
non-exclusive distribution agreement with the CTC Group to
incorporate SlimBiome(R) into a range of applications targeting
hunger free sustainable weight loss. This extends our
commercialisation of SlimBiome(R) into ASEAN markets where we have
identified a strong consumer need for both weight loss and weight
management products. CTC conducted a trial of SlimBiome in
OptiBiotix's GoFigure's products which showed an average weight
loss of 3lbs per week. This is consistent with OptiBiotix's own
scientific and consumer studies which show these food products help
customers to manage their weight loss by reducing food intake
without food cravings. As we build the range of applications,
products and geographic scope of SlimBiome(R) with new partners,
the scale of the opportunity enlarges, allowing us to fully exploit
the revenue generating potential of this ground-breaking
technology."
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook
below
Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213 0880
Liam Murray / Jo Turner
finnCap (Broker) Tel: 020 7220 0500
Geoff Nash/ Scott Mathieson / Kate Bannatyne
(Corporate Finance)
Camille Gochez (Corporate Broking)
Walbrook PR Ltd Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Anna Dunphy Mob: 07876 741 001
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March
2012, brings science to the development of compounds which modify
the human microbiome - the collective genome of the microbes in the
body - in order to prevent and manage human disease and promote
wellness.
OptiBiotix has an extensive R&D program working with leading
academics in the development of microbial strains, compounds, and
formulations which are used as active ingredients and supplements.
More than twenty international food and healthcare supplement
companies have signed agreements with OptiBiotix to incorporate
their human microbiome modulators into a wide range of food
products and drinks.
OptiBiotix is also developing its own range of consumer
supplements and health products. The Company's current areas of
focus include obesity, cardiovascular health, and diabetes.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
AGRZMGZLMRDGRZM
(END) Dow Jones Newswires
October 01, 2018 02:00 ET (06:00 GMT)
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Sep 2023 to Sep 2024